Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, a part of the retina responsible for central vision. The cells in the macula become damaged and begin to die, causing vision loss as a person ages. The disease is typically categorized into two types: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common and involves the formation of small, yellow deposits in the macula, while wet AMD is less common and involves the growth of abnormal blood vessels beneath the macula. In dry AMD, treatment options include vitamin supplements and lifestyle changes to reduce risk factors. In wet AMD, treatment involves medications that are injected into the eye to stop the growth of abnormal blood vessels. This treatment is called abnormal endothelial growth factor (anti-VEGF) therapy, and it works by blocking the protein that stimulates the growth of abnormal blood vessels.
The global Age-Related Macular Degeneration (AMD) Treatment Drugs market size is projected to grow from US$ 10480 million in 2024 to US$ 14800 million in 2030; it is expected to grow at a CAGR of 5.9% from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Forecast” looks at past sales and reviews total world Age-Related Macular Degeneration (AMD) Treatment Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Age-Related Macular Degeneration (AMD) Treatment Drugs sales for 2024 through 2030. With Age-Related Macular Degeneration (AMD) Treatment Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Age-Related Macular Degeneration (AMD) Treatment Drugs industry.
This Insight Report provides a comprehensive analysis of the global Age-Related Macular Degeneration (AMD) Treatment Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Age-Related Macular Degeneration (AMD) Treatment Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Age-Related Macular Degeneration (AMD) Treatment Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Age-Related Macular Degeneration (AMD) Treatment Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Age-Related Macular Degeneration (AMD) Treatment Drugs.
The age-related macular degeneration (AMD) market trends are shaping the growth of the market. For instance rise in the adoption of age-related macular degeneration drugs (AMD) among the geriatric population suffering from age-related macular degeneration (AMD) drives the growth of the age-related macular degeneration (AMD) market size. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over, indicating a potential increase in the age-related macular degeneration (AMD) market size.
This report presents a comprehensive overview, market shares, and growth opportunities of Age-Related Macular Degeneration (AMD) Treatment Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Age-Related Macular Degeneration (AMD) Treatment Drugs market?
What factors are driving Age-Related Macular Degeneration (AMD) Treatment Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Age-Related Macular Degeneration (AMD) Treatment Drugs market opportunities vary by end market size?
How does Age-Related Macular Degeneration (AMD) Treatment Drugs break out by Type, by Application?
Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, a part of the retina responsible for central vision. The cells in the macula become damaged and begin to die, causing vision loss as a person ages. The disease is typically categorized into two types: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common and involves the formation of small, yellow deposits in the macula, while wet AMD is less common and involves the growth of abnormal blood vessels beneath the macula. In dry AMD, treatment options include vitamin supplements and lifestyle changes to reduce risk factors. In wet AMD, treatment involves medications that are injected into the eye to stop the growth of abnormal blood vessels. This treatment is called abnormal endothelial growth factor (anti-VEGF) therapy, and it works by blocking the protein that stimulates the growth of abnormal blood vessels.
The global Age-Related Macular Degeneration (AMD) Treatment Drugs market size is projected to grow from US$ 10480 million in 2024 to US$ 14800 million in 2030; it is expected to grow at a CAGR of 5.9% from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Forecast” looks at past sales and reviews total world Age-Related Macular Degeneration (AMD) Treatment Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Age-Related Macular Degeneration (AMD) Treatment Drugs sales for 2024 through 2030. With Age-Related Macular Degeneration (AMD) Treatment Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Age-Related Macular Degeneration (AMD) Treatment Drugs industry.
This Insight Report provides a comprehensive analysis of the global Age-Related Macular Degeneration (AMD) Treatment Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Age-Related Macular Degeneration (AMD) Treatment Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Age-Related Macular Degeneration (AMD) Treatment Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Age-Related Macular Degeneration (AMD) Treatment Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Age-Related Macular Degeneration (AMD) Treatment Drugs.
The age-related macular degeneration (AMD) market trends are shaping the growth of the market. For instance rise in the adoption of age-related macular degeneration drugs (AMD) among the geriatric population suffering from age-related macular degeneration (AMD) drives the growth of the age-related macular degeneration (AMD) market size. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over, indicating a potential increase in the age-related macular degeneration (AMD) market size.
This report presents a comprehensive overview, market shares, and growth opportunities of Age-Related Macular Degeneration (AMD) Treatment Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Aflibercept
- Ranibizumab
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Ionis Pharmaceuticals, Inc
- Bausch Health Companies Inc
- Regeneron Pharmaceuticals Inc
- Biogen
- Novartis AG
- Sanofi S.A.
- Bayer AG
- Coherus Biosciences Inc
- F. Hoffmann-La Roche Ltd
- Apellis Pharmaceuticals Inc
- AbbVie
- Pfizer Inc.
- Amgen Inc.
- Samsung Bioepis
What is the 10-year outlook for the global Age-Related Macular Degeneration (AMD) Treatment Drugs market?
What factors are driving Age-Related Macular Degeneration (AMD) Treatment Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Age-Related Macular Degeneration (AMD) Treatment Drugs market opportunities vary by end market size?
How does Age-Related Macular Degeneration (AMD) Treatment Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Age-Related Macular Degeneration (AMD) Treatment Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Age-Related Macular Degeneration (AMD) Treatment Drugs by Country/Region, 2019, 2023 & 2030
2.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Segment by Type
2.2.1 Aflibercept
2.2.2 Ranibizumab
2.2.3 Others
2.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type
2.3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Price by Type (2019-2024)
2.4 Age-Related Macular Degeneration (AMD) Treatment Drugs Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.5 Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application
2.5.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Breakdown Data by Company
3.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Company (2019-2024)
3.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (2019-2024)
3.2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Price by Company
3.4 Key Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Product Location Distribution
3.4.2 Players Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR AGE-RELATED MACULAR DEGENERATION (AMD) TREATMENT DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Growth
4.4 APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Growth
4.5 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Growth
4.6 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Growth
5 AMERICAS
5.1 Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country
5.1.1 Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024)
5.1.2 Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024)
5.2 Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024)
5.3 Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region
6.1.1 APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2019-2024)
6.1.2 APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2019-2024)
6.2 APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024)
6.3 APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs by Country
7.1.1 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024)
7.1.2 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024)
7.2 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024)
7.3 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs by Country
8.1.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024)
8.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs
10.3 Manufacturing Process Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs
10.4 Industry Chain Structure of Age-Related Macular Degeneration (AMD) Treatment Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Distributors
11.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Customer
12 WORLD FORECAST REVIEW FOR AGE-RELATED MACULAR DEGENERATION (AMD) TREATMENT DRUGS BY GEOGRAPHIC REGION
12.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Forecast by Region
12.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Forecast by Region (2025-2030)
12.1.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Forecast by Type (2025-2030)
12.7 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Ionis Pharmaceuticals, Inc
13.1.1 Ionis Pharmaceuticals, Inc Company Information
13.1.2 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.1.3 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Ionis Pharmaceuticals, Inc Main Business Overview
13.1.5 Ionis Pharmaceuticals, Inc Latest Developments
13.2 Bausch Health Companies Inc
13.2.1 Bausch Health Companies Inc Company Information
13.2.2 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.2.3 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bausch Health Companies Inc Main Business Overview
13.2.5 Bausch Health Companies Inc Latest Developments
13.3 Regeneron Pharmaceuticals Inc
13.3.1 Regeneron Pharmaceuticals Inc Company Information
13.3.2 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.3.3 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Regeneron Pharmaceuticals Inc Main Business Overview
13.3.5 Regeneron Pharmaceuticals Inc Latest Developments
13.4 Biogen
13.4.1 Biogen Company Information
13.4.2 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.4.3 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Biogen Main Business Overview
13.4.5 Biogen Latest Developments
13.5 Novartis AG
13.5.1 Novartis AG Company Information
13.5.2 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.5.3 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Novartis AG Main Business Overview
13.5.5 Novartis AG Latest Developments
13.6 Sanofi S.A.
13.6.1 Sanofi S.A. Company Information
13.6.2 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.6.3 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Sanofi S.A. Main Business Overview
13.6.5 Sanofi S.A. Latest Developments
13.7 Bayer AG
13.7.1 Bayer AG Company Information
13.7.2 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.7.3 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Bayer AG Main Business Overview
13.7.5 Bayer AG Latest Developments
13.8 Coherus Biosciences Inc
13.8.1 Coherus Biosciences Inc Company Information
13.8.2 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.8.3 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Coherus Biosciences Inc Main Business Overview
13.8.5 Coherus Biosciences Inc Latest Developments
13.9 F. Hoffmann-La Roche Ltd
13.9.1 F. Hoffmann-La Roche Ltd Company Information
13.9.2 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.9.3 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.9.5 F. Hoffmann-La Roche Ltd Latest Developments
13.10 Apellis Pharmaceuticals Inc
13.10.1 Apellis Pharmaceuticals Inc Company Information
13.10.2 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.10.3 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Apellis Pharmaceuticals Inc Main Business Overview
13.10.5 Apellis Pharmaceuticals Inc Latest Developments
13.11 AbbVie
13.11.1 AbbVie Company Information
13.11.2 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.11.3 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 AbbVie Main Business Overview
13.11.5 AbbVie Latest Developments
13.12 Pfizer Inc.
13.12.1 Pfizer Inc. Company Information
13.12.2 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.12.3 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Pfizer Inc. Main Business Overview
13.12.5 Pfizer Inc. Latest Developments
13.13 Amgen Inc.
13.13.1 Amgen Inc. Company Information
13.13.2 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.13.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Amgen Inc. Main Business Overview
13.13.5 Amgen Inc. Latest Developments
13.14 Samsung Bioepis
13.14.1 Samsung Bioepis Company Information
13.14.2 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.14.3 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Samsung Bioepis Main Business Overview
13.14.5 Samsung Bioepis Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Age-Related Macular Degeneration (AMD) Treatment Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Age-Related Macular Degeneration (AMD) Treatment Drugs by Country/Region, 2019, 2023 & 2030
2.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Segment by Type
2.2.1 Aflibercept
2.2.2 Ranibizumab
2.2.3 Others
2.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type
2.3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Price by Type (2019-2024)
2.4 Age-Related Macular Degeneration (AMD) Treatment Drugs Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.5 Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application
2.5.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Breakdown Data by Company
3.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Company (2019-2024)
3.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (2019-2024)
3.2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Price by Company
3.4 Key Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Product Location Distribution
3.4.2 Players Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR AGE-RELATED MACULAR DEGENERATION (AMD) TREATMENT DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Growth
4.4 APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Growth
4.5 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Growth
4.6 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Growth
5 AMERICAS
5.1 Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country
5.1.1 Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024)
5.1.2 Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024)
5.2 Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024)
5.3 Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region
6.1.1 APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2019-2024)
6.1.2 APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2019-2024)
6.2 APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024)
6.3 APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs by Country
7.1.1 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024)
7.1.2 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024)
7.2 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024)
7.3 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs by Country
8.1.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024)
8.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs
10.3 Manufacturing Process Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs
10.4 Industry Chain Structure of Age-Related Macular Degeneration (AMD) Treatment Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Distributors
11.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Customer
12 WORLD FORECAST REVIEW FOR AGE-RELATED MACULAR DEGENERATION (AMD) TREATMENT DRUGS BY GEOGRAPHIC REGION
12.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Forecast by Region
12.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Forecast by Region (2025-2030)
12.1.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Forecast by Type (2025-2030)
12.7 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Ionis Pharmaceuticals, Inc
13.1.1 Ionis Pharmaceuticals, Inc Company Information
13.1.2 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.1.3 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Ionis Pharmaceuticals, Inc Main Business Overview
13.1.5 Ionis Pharmaceuticals, Inc Latest Developments
13.2 Bausch Health Companies Inc
13.2.1 Bausch Health Companies Inc Company Information
13.2.2 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.2.3 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bausch Health Companies Inc Main Business Overview
13.2.5 Bausch Health Companies Inc Latest Developments
13.3 Regeneron Pharmaceuticals Inc
13.3.1 Regeneron Pharmaceuticals Inc Company Information
13.3.2 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.3.3 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Regeneron Pharmaceuticals Inc Main Business Overview
13.3.5 Regeneron Pharmaceuticals Inc Latest Developments
13.4 Biogen
13.4.1 Biogen Company Information
13.4.2 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.4.3 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Biogen Main Business Overview
13.4.5 Biogen Latest Developments
13.5 Novartis AG
13.5.1 Novartis AG Company Information
13.5.2 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.5.3 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Novartis AG Main Business Overview
13.5.5 Novartis AG Latest Developments
13.6 Sanofi S.A.
13.6.1 Sanofi S.A. Company Information
13.6.2 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.6.3 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Sanofi S.A. Main Business Overview
13.6.5 Sanofi S.A. Latest Developments
13.7 Bayer AG
13.7.1 Bayer AG Company Information
13.7.2 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.7.3 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Bayer AG Main Business Overview
13.7.5 Bayer AG Latest Developments
13.8 Coherus Biosciences Inc
13.8.1 Coherus Biosciences Inc Company Information
13.8.2 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.8.3 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Coherus Biosciences Inc Main Business Overview
13.8.5 Coherus Biosciences Inc Latest Developments
13.9 F. Hoffmann-La Roche Ltd
13.9.1 F. Hoffmann-La Roche Ltd Company Information
13.9.2 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.9.3 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.9.5 F. Hoffmann-La Roche Ltd Latest Developments
13.10 Apellis Pharmaceuticals Inc
13.10.1 Apellis Pharmaceuticals Inc Company Information
13.10.2 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.10.3 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Apellis Pharmaceuticals Inc Main Business Overview
13.10.5 Apellis Pharmaceuticals Inc Latest Developments
13.11 AbbVie
13.11.1 AbbVie Company Information
13.11.2 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.11.3 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 AbbVie Main Business Overview
13.11.5 AbbVie Latest Developments
13.12 Pfizer Inc.
13.12.1 Pfizer Inc. Company Information
13.12.2 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.12.3 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Pfizer Inc. Main Business Overview
13.12.5 Pfizer Inc. Latest Developments
13.13 Amgen Inc.
13.13.1 Amgen Inc. Company Information
13.13.2 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.13.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Amgen Inc. Main Business Overview
13.13.5 Amgen Inc. Latest Developments
13.14 Samsung Bioepis
13.14.1 Samsung Bioepis Company Information
13.14.2 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
13.14.3 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Samsung Bioepis Main Business Overview
13.14.5 Samsung Bioepis Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Aflibercept
Table 4. Major Players of Ranibizumab
Table 5. Major Players of Others
Table 6. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024) & (K Dose)
Table 7. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
Table 8. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type (2019-2024) & ($ million)
Table 9. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Type (2019-2024)
Table 10. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Price by Type (2019-2024) & (US$/Dose)
Table 11. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale by Application (2019-2024) & (K Dose)
Table 12. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Market Share by Application (2019-2024)
Table 13. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Application (2019-2024) & ($ million)
Table 14. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application (2019-2024)
Table 15. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Price by Application (2019-2024) & (US$/Dose)
Table 16. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company (2019-2024) & (K Dose)
Table 17. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Company (2019-2024)
Table 18. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (2019-2024) & ($ millions)
Table 19. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Company (2019-2024)
Table 20. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Price by Company (2019-2024) & (US$/Dose)
Table 21. Key Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Producing Area Distribution and Sales Area
Table 22. Players Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
Table 23. Age-Related Macular Degeneration (AMD) Treatment Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Geographic Region (2019-2024) & (K Dose)
Table 27. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share Geographic Region (2019-2024)
Table 28. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country/Region (2019-2024) & (K Dose)
Table 31. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country/Region (2019-2024)
Table 32. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024) & (K Dose)
Table 35. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country (2019-2024)
Table 36. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024) & ($ millions)
Table 37. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024) & (K Dose)
Table 38. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024) & (K Dose)
Table 39. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2019-2024) & (K Dose)
Table 40. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Region (2019-2024)
Table 41. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2019-2024) & ($ millions)
Table 42. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024) & (K Dose)
Table 43. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024) & (K Dose)
Table 44. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024) & (K Dose)
Table 45. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024) & ($ millions)
Table 46. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024) & (K Dose)
Table 47. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024) & (K Dose)
Table 48. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024) & (K Dose)
Table 49. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Country (2019-2024)
Table 50. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024) & (K Dose)
Table 51. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024) & (K Dose)
Table 52. Key Market Drivers & Growth Opportunities of Age-Related Macular Degeneration (AMD) Treatment Drugs
Table 53. Key Market Challenges & Risks of Age-Related Macular Degeneration (AMD) Treatment Drugs
Table 54. Key Industry Trends of Age-Related Macular Degeneration (AMD) Treatment Drugs
Table 55. Age-Related Macular Degeneration (AMD) Treatment Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Age-Related Macular Degeneration (AMD) Treatment Drugs Distributors List
Table 58. Age-Related Macular Degeneration (AMD) Treatment Drugs Customer List
Table 59. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Region (2025-2030) & (K Dose)
Table 60. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 61. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Country (2025-2030) & (K Dose)
Table 62. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 63. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Region (2025-2030) & (K Dose)
Table 64. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 65. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Country (2025-2030) & (K Dose)
Table 66. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 67. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Country (2025-2030) & (K Dose)
Table 68. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Type (2025-2030) & (K Dose)
Table 70. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Type (2025-2030) & ($ millions)
Table 71. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Application (2025-2030) & (K Dose)
Table 72. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Application (2025-2030) & ($ millions)
Table 73. Ionis Pharmaceuticals, Inc Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 75. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 76. Ionis Pharmaceuticals, Inc Main Business
Table 77. Ionis Pharmaceuticals, Inc Latest Developments
Table 78. Bausch Health Companies Inc Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 80. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 81. Bausch Health Companies Inc Main Business
Table 82. Bausch Health Companies Inc Latest Developments
Table 83. Regeneron Pharmaceuticals Inc Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 85. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 86. Regeneron Pharmaceuticals Inc Main Business
Table 87. Regeneron Pharmaceuticals Inc Latest Developments
Table 88. Biogen Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 90. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 91. Biogen Main Business
Table 92. Biogen Latest Developments
Table 93. Novartis AG Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 95. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 96. Novartis AG Main Business
Table 97. Novartis AG Latest Developments
Table 98. Sanofi S.A. Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 100. Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 101. Sanofi S.A. Main Business
Table 102. Sanofi S.A. Latest Developments
Table 103. Bayer AG Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 105. Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 106. Bayer AG Main Business
Table 107. Bayer AG Latest Developments
Table 108. Coherus Biosciences Inc Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 110. Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 111. Coherus Biosciences Inc Main Business
Table 112. Coherus Biosciences Inc Latest Developments
Table 113. F. Hoffmann-La Roche Ltd Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 115. F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 116. F. Hoffmann-La Roche Ltd Main Business
Table 117. F. Hoffmann-La Roche Ltd Latest Developments
Table 118. Apellis Pharmaceuticals Inc Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 120. Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 121. Apellis Pharmaceuticals Inc Main Business
Table 122. Apellis Pharmaceuticals Inc Latest Developments
Table 123. AbbVie Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 125. AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 126. AbbVie Main Business
Table 127. AbbVie Latest Developments
Table 128. Pfizer Inc. Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 130. Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 131. Pfizer Inc. Main Business
Table 132. Pfizer Inc. Latest Developments
Table 133. Amgen Inc. Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 135. Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 136. Amgen Inc. Main Business
Table 137. Amgen Inc. Latest Developments
Table 138. Samsung Bioepis Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 140. Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 141. Samsung Bioepis Main Business
Table 142. Samsung Bioepis Latest Developments
Table 1. Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Aflibercept
Table 4. Major Players of Ranibizumab
Table 5. Major Players of Others
Table 6. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024) & (K Dose)
Table 7. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
Table 8. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type (2019-2024) & ($ million)
Table 9. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Type (2019-2024)
Table 10. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Price by Type (2019-2024) & (US$/Dose)
Table 11. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale by Application (2019-2024) & (K Dose)
Table 12. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Market Share by Application (2019-2024)
Table 13. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Application (2019-2024) & ($ million)
Table 14. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application (2019-2024)
Table 15. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Price by Application (2019-2024) & (US$/Dose)
Table 16. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company (2019-2024) & (K Dose)
Table 17. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Company (2019-2024)
Table 18. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (2019-2024) & ($ millions)
Table 19. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Company (2019-2024)
Table 20. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Price by Company (2019-2024) & (US$/Dose)
Table 21. Key Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Producing Area Distribution and Sales Area
Table 22. Players Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
Table 23. Age-Related Macular Degeneration (AMD) Treatment Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Geographic Region (2019-2024) & (K Dose)
Table 27. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share Geographic Region (2019-2024)
Table 28. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country/Region (2019-2024) & (K Dose)
Table 31. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country/Region (2019-2024)
Table 32. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024) & (K Dose)
Table 35. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country (2019-2024)
Table 36. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024) & ($ millions)
Table 37. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024) & (K Dose)
Table 38. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024) & (K Dose)
Table 39. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2019-2024) & (K Dose)
Table 40. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Region (2019-2024)
Table 41. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2019-2024) & ($ millions)
Table 42. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024) & (K Dose)
Table 43. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024) & (K Dose)
Table 44. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024) & (K Dose)
Table 45. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024) & ($ millions)
Table 46. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024) & (K Dose)
Table 47. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024) & (K Dose)
Table 48. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024) & (K Dose)
Table 49. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Country (2019-2024)
Table 50. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024) & (K Dose)
Table 51. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024) & (K Dose)
Table 52. Key Market Drivers & Growth Opportunities of Age-Related Macular Degeneration (AMD) Treatment Drugs
Table 53. Key Market Challenges & Risks of Age-Related Macular Degeneration (AMD) Treatment Drugs
Table 54. Key Industry Trends of Age-Related Macular Degeneration (AMD) Treatment Drugs
Table 55. Age-Related Macular Degeneration (AMD) Treatment Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Age-Related Macular Degeneration (AMD) Treatment Drugs Distributors List
Table 58. Age-Related Macular Degeneration (AMD) Treatment Drugs Customer List
Table 59. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Region (2025-2030) & (K Dose)
Table 60. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 61. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Country (2025-2030) & (K Dose)
Table 62. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 63. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Region (2025-2030) & (K Dose)
Table 64. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 65. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Country (2025-2030) & (K Dose)
Table 66. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 67. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Country (2025-2030) & (K Dose)
Table 68. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Type (2025-2030) & (K Dose)
Table 70. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Type (2025-2030) & ($ millions)
Table 71. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Application (2025-2030) & (K Dose)
Table 72. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Application (2025-2030) & ($ millions)
Table 73. Ionis Pharmaceuticals, Inc Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 75. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 76. Ionis Pharmaceuticals, Inc Main Business
Table 77. Ionis Pharmaceuticals, Inc Latest Developments
Table 78. Bausch Health Companies Inc Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 80. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 81. Bausch Health Companies Inc Main Business
Table 82. Bausch Health Companies Inc Latest Developments
Table 83. Regeneron Pharmaceuticals Inc Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 85. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 86. Regeneron Pharmaceuticals Inc Main Business
Table 87. Regeneron Pharmaceuticals Inc Latest Developments
Table 88. Biogen Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 90. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 91. Biogen Main Business
Table 92. Biogen Latest Developments
Table 93. Novartis AG Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 95. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 96. Novartis AG Main Business
Table 97. Novartis AG Latest Developments
Table 98. Sanofi S.A. Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 100. Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 101. Sanofi S.A. Main Business
Table 102. Sanofi S.A. Latest Developments
Table 103. Bayer AG Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 105. Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 106. Bayer AG Main Business
Table 107. Bayer AG Latest Developments
Table 108. Coherus Biosciences Inc Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 110. Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 111. Coherus Biosciences Inc Main Business
Table 112. Coherus Biosciences Inc Latest Developments
Table 113. F. Hoffmann-La Roche Ltd Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 115. F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 116. F. Hoffmann-La Roche Ltd Main Business
Table 117. F. Hoffmann-La Roche Ltd Latest Developments
Table 118. Apellis Pharmaceuticals Inc Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 120. Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 121. Apellis Pharmaceuticals Inc Main Business
Table 122. Apellis Pharmaceuticals Inc Latest Developments
Table 123. AbbVie Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 125. AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 126. AbbVie Main Business
Table 127. AbbVie Latest Developments
Table 128. Pfizer Inc. Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 130. Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 131. Pfizer Inc. Main Business
Table 132. Pfizer Inc. Latest Developments
Table 133. Amgen Inc. Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 135. Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 136. Amgen Inc. Main Business
Table 137. Amgen Inc. Latest Developments
Table 138. Samsung Bioepis Basic Information, Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolios and Specifications
Table 140. Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 141. Samsung Bioepis Main Business
Table 142. Samsung Bioepis Latest Developments
LIST OF FIGURES
Figure 1. Picture of Age-Related Macular Degeneration (AMD) Treatment Drugs
Figure 2. Age-Related Macular Degeneration (AMD) Treatment Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country/Region (2023)
Figure 10. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Aflibercept
Figure 12. Product Picture of Ranibizumab
Figure 13. Product Picture of Others
Figure 14. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type in 2023
Figure 15. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Type (2019-2024)
Figure 16. Age-Related Macular Degeneration (AMD) Treatment Drugs Consumed in Hospital Pharmacy
Figure 17. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Hospital Pharmacy (2019-2024) & (K Dose)
Figure 18. Age-Related Macular Degeneration (AMD) Treatment Drugs Consumed in Retail Pharmacy
Figure 19. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Retail Pharmacy (2019-2024) & (K Dose)
Figure 20. Age-Related Macular Degeneration (AMD) Treatment Drugs Consumed in Online Pharmacy
Figure 21. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Online Pharmacy (2019-2024) & (K Dose)
Figure 22. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Market Share by Application (2023)
Figure 23. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application in 2023
Figure 24. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company in 2023 (K Dose)
Figure 25. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Company in 2023
Figure 26. Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company in 2023 ($ millions)
Figure 27. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Company in 2023
Figure 28. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 29. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Geographic Region in 2023
Figure 30. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales 2019-2024 (K Dose)
Figure 31. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue 2019-2024 ($ millions)
Figure 32. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales 2019-2024 (K Dose)
Figure 33. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue 2019-2024 ($ millions)
Figure 34. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales 2019-2024 (K Dose)
Figure 35. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue 2019-2024 ($ millions)
Figure 36. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales 2019-2024 (K Dose)
Figure 37. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue 2019-2024 ($ millions)
Figure 38. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country in 2023
Figure 39. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Country (2019-2024)
Figure 40. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
Figure 41. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2019-2024)
Figure 42. United States Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 43. Canada Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 44. Mexico Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 45. Brazil Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 46. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Region in 2023
Figure 47. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Region (2019-2024)
Figure 48. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
Figure 49. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2019-2024)
Figure 50. China Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 51. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 52. South Korea Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 53. Southeast Asia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 54. India Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 55. Australia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 56. China Taiwan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 57. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country in 2023
Figure 58. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Country (2019-2024)
Figure 59. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
Figure 60. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2019-2024)
Figure 61. Germany Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 62. France Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 63. UK Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 64. Italy Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 65. Russia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 66. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country (2019-2024)
Figure 67. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
Figure 68. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2019-2024)
Figure 69. Egypt Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 70. South Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 71. Israel Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 72. Turkey Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 73. GCC Countries Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs in 2023
Figure 75. Manufacturing Process Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs
Figure 76. Industry Chain Structure of Age-Related Macular Degeneration (AMD) Treatment Drugs
Figure 77. Channels of Distribution
Figure 78. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Forecast by Region (2025-2030)
Figure 79. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 80. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 81. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 82. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share Forecast by Application (2025-2030)
Figure 83. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Age-Related Macular Degeneration (AMD) Treatment Drugs
Figure 2. Age-Related Macular Degeneration (AMD) Treatment Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country/Region (2023)
Figure 10. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Aflibercept
Figure 12. Product Picture of Ranibizumab
Figure 13. Product Picture of Others
Figure 14. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type in 2023
Figure 15. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Type (2019-2024)
Figure 16. Age-Related Macular Degeneration (AMD) Treatment Drugs Consumed in Hospital Pharmacy
Figure 17. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Hospital Pharmacy (2019-2024) & (K Dose)
Figure 18. Age-Related Macular Degeneration (AMD) Treatment Drugs Consumed in Retail Pharmacy
Figure 19. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Retail Pharmacy (2019-2024) & (K Dose)
Figure 20. Age-Related Macular Degeneration (AMD) Treatment Drugs Consumed in Online Pharmacy
Figure 21. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Online Pharmacy (2019-2024) & (K Dose)
Figure 22. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sale Market Share by Application (2023)
Figure 23. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application in 2023
Figure 24. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company in 2023 (K Dose)
Figure 25. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Company in 2023
Figure 26. Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company in 2023 ($ millions)
Figure 27. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Company in 2023
Figure 28. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 29. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Geographic Region in 2023
Figure 30. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales 2019-2024 (K Dose)
Figure 31. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue 2019-2024 ($ millions)
Figure 32. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales 2019-2024 (K Dose)
Figure 33. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue 2019-2024 ($ millions)
Figure 34. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales 2019-2024 (K Dose)
Figure 35. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue 2019-2024 ($ millions)
Figure 36. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales 2019-2024 (K Dose)
Figure 37. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue 2019-2024 ($ millions)
Figure 38. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country in 2023
Figure 39. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Country (2019-2024)
Figure 40. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
Figure 41. Americas Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2019-2024)
Figure 42. United States Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 43. Canada Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 44. Mexico Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 45. Brazil Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 46. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Region in 2023
Figure 47. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Region (2019-2024)
Figure 48. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
Figure 49. APAC Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2019-2024)
Figure 50. China Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 51. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 52. South Korea Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 53. Southeast Asia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 54. India Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 55. Australia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 56. China Taiwan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 57. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country in 2023
Figure 58. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Country (2019-2024)
Figure 59. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
Figure 60. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2019-2024)
Figure 61. Germany Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 62. France Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 63. UK Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 64. Italy Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 65. Russia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 66. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country (2019-2024)
Figure 67. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
Figure 68. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2019-2024)
Figure 69. Egypt Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 70. South Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 71. Israel Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 72. Turkey Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 73. GCC Countries Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth 2019-2024 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs in 2023
Figure 75. Manufacturing Process Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs
Figure 76. Industry Chain Structure of Age-Related Macular Degeneration (AMD) Treatment Drugs
Figure 77. Channels of Distribution
Figure 78. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Forecast by Region (2025-2030)
Figure 79. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 80. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 81. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 82. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share Forecast by Application (2025-2030)
Figure 83. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share Forecast by Application (2025-2030)
